GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug

Posted by |2019-08-23T12:46:07-07:00August 23rd, 2019|

An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year. GlaxoSmithKline (NYSE: GSK) said Friday that treatment with its drug, belantamab mafodotin, showed a “clinically meaningful overall response rate” in the study. The […]

New BC Biotech Chinook Reels in $65M to Tackle Kidney Disease

Posted by |2019-08-22T14:19:04-07:00August 22nd, 2019|

About 15 percent of adults in the US, or around 37 million people, are estimated to have chronic kidney disease, according to the Centers for Disease Control. There are very few therapeutic options for them, which means they often progress to kidney failure, which is treatable only with dialysis or transplant. Chinook Therapeutics is looking […]

Healthcare’s Future is Telemedicine & AI, But Will Everyone Benefit?

Posted by |2019-08-21T20:01:26-07:00August 21st, 2019|

John Halamka thinks the digital health industry is still “emerging.” But it has come a long way and is starting to deliver after years of hype. Halamka, a Boston-based physician and healthcare technology expert, says that’s thanks to several coalescing factors: improved technology, more favorable financial incentives for using digital products in healthcare, and growing […]

Elanco’s $7.6B Deal With Bayer Bolsters Pets, Farm Animals Footprint

Posted by |2019-08-20T09:35:36-07:00August 20th, 2019|

Elanco Animal Health, the veterinary sector’s fourth-largest company measured by revenue, is poised to leap to number two through a $7.6 billion cash and stock deal for Bayer’s animal health unit. The acquisition will help Elanco boost its business selling products for farm animals. But Elanco (NYSE: ELAN) notes that Bayer, which sells the popular […]

FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns

Posted by |2019-08-19T14:44:46-07:00August 19th, 2019|

Sarepta Therapeutics won one of the most dramatic and controversial drug approvals in the history of the FDA a few years ago. It didn’t have the same luck the second time around. The FDA late Monday rejected golodirsen (Vyondys 53), which was widely expected to become the second approved Duchenne muscular dystrophy drug from Sarepta […]

Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs

Posted by |2019-08-19T03:30:06-07:00August 16th, 2019|

The dog days of summer are here and IPO activity has slowed, but that hasn’t stopped some biotech companies from securing a place in the line leading to Wall Street. Late Friday, SpringWorks Therapeutics and Satsuma Pharmaceuticals filed paperwork to go public. SpringWorks spun out of Pfizer (NYSE: PFE) nearly two years ago, aiming to […]

SpringWorks Therapeutics Appoints Francis Perier CFO

Posted by |2019-08-15T08:57:35-07:00August 15th, 2019|

Francis Perier has been appointed chief financial officer of SpringWorks Therapeutics. Perier’s experience includes financial roles at Forest Laboratories, Bristol-Myers Squibb (NYSE: BMY), and Deloitte. Stamford, CT-based SpringWorks was spun out of Pfizer (NYSE: PFE) in 2017 with rights to four of the pharmaceutical giant’s drugs. In April, SpringWorks raised $125 million in Series B […]

Ex-Acceleron Exec Zeldin Named Immunovant Chief Medical Officer

Posted by |2019-08-14T11:07:27-07:00August 14th, 2019|

Four months after stepping down from Acceleron Pharma (NASDAQ: XLRN) as chief medical officer, Robert Zeldin has been appointed to the chief medical position at Immunovant. Zeldin’s experience also includes roles at Ablynx, Merck (NYSE: MRK), and Novartis (NYSE: NVS). Immunovant, which splits its operations between New York and Basel, Switzerland, is developing treatments for […]

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug

Posted by |2019-08-13T04:23:23-07:00August 13th, 2019|

[Updated, 11:04 am ET, see below] Deciphera Pharmaceuticals this morning announced plans to seek FDA approval of a cancer medicine that treats a deadly type of tumor that forms in the gastrointestinal tract. The Deciphera (NASDASQ: DCPH) drug, ripretinib, hit its main goal in a Phase 3 trial, INVICTUS, in 129 patients with gastrointestinal stromal […]

GSK’s US President Bailey to Depart, EMD Serono Exec Named Successor

Posted by |2019-08-12T10:42:51-07:00August 12th, 2019|

Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline (NYSE: GSK), will step down from the role at the end of the year. The British pharmaceutical giant said Monday that Bailey will be succeeded by Maya Martinez-Davis, regional president of Latin America for EMD Serono, the biopharma business of Germany-based Merck KGaA. Martinez-Davis’s experience also includes […]

Melinta Therapeutics CEO Johnson Resigns, Successor Search Underway

Posted by |2019-08-12T03:30:05-07:00August 9th, 2019|

After less than one year on the job, Melinta Therapeutics (NASDAQ: MLNT) CEO John Johnson has resigned “due to changes in the company’s circumstances and in order to pursue other opportunities,” the antibiotics developer announced Friday. He also stepped down from the Morristown, NJ-based company’s board of directors. Melinta said Johnson will serve as acting […]

Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work

Posted by |2019-08-08T02:55:45-07:00August 8th, 2019|

Versant Ventures and Bayer have started several biotechs together. But today marks the first time the German drug maker takes a step further and buys one of them: cell therapy developer BlueRock Therapeutics. Bayer already owns a 40.8 percent stake in BlueRock through its Leaps by Bayer venture arm. But it will pay $240 million […]

Load More Posts